

# Engineered in India “ Patent Law 2.0

New England Journal of Medicine

369, 497-499

DOI: 10.1056/nejmp1304400

Citation Report

#	ARTICLE	IF	CITATIONS
1	Engineered in India – Patent Law 2.0. <i>New England Journal of Medicine</i> , 2013, 369, 2163-2163.	27.0	7
2	Generic Imatinib: The real-deal or just a deal?. <i>Leukemia and Lymphoma</i> , 2014, , 1-8.	1.3	4
3	Generic imatinib: the real-deal or just a deal?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2678-2680.	1.3	13
4	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology</i> , The, 2014, 15, 489-538.	10.7	411
5	Global Health and the Law. <i>New England Journal of Medicine</i> , 2014, 370, 1732-1740.	27.0	95
6	Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. <i>Clinical Infectious Diseases</i> , 2014, 58, 928-936.	5.8	197
7	The Hidden Cost Of Low Prices: Limited Access To New Drugs In India. <i>Health Affairs</i> , 2014, 33, 1567-1575.	5.2	31
8	Delivery of affordable and equitable cancer care in India. <i>Lancet Oncology</i> , The, 2014, 15, e223-e233.	10.7	169
9	The Trans-Pacific Partnership – Is It Bad for Your Health?. <i>New England Journal of Medicine</i> , 2015, 373, 201-203.	27.0	15
10	The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1563.	7.4	8
11	Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia. <i>Journal of Chemotherapy</i> , 2015, 27, 337-342.	1.5	11
12	Management of multiple myeloma in resource-constrained settings. <i>Seminars in Oncology</i> , 2016, 43, 690-694.	2.2	4
13	Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 12.	2.4	23
14	Secondary pharmaceutical patenting: A global perspective. <i>Research Policy</i> , 2017, 46, 693-707.	6.4	35
15	The Emergence of Interjudicial Cooperation among National Courts. , 0, , 105-148.		0
17	The Road to Addressing Noncommunicable Diseases and Cancer in Global Health Policy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 29-33.	3.8	1
19	Evergreening of pharmaceutical patents: A blithe disregard for the rationale of the patent system. <i>Journal of Generic Medicines</i> , 2019, 15, 53-60.	0.2	1
20	India, Brazil, and public health: Rule-making through south-south diffusion in the intellectual property rights regime?. <i>Regulation and Governance</i> , 2021, 15, 616-633.	2.9	4

#	ARTICLE	IF	CITATIONS
21	Power Shifts in International Law: Structural Realignment and Substantive Pluralism. SSRN Electronic Journal, 0, , .	0.4	7
22	Generic drugs: Review and experiences from South India. Journal of Family Medicine and Primary Care, 2015, 4, 319.	0.9	21
23	From AIDS to cancer: health activism, biotechnology and intellectual property in South Africa. Social Dynamics, 2020, 46, 449-470.	0.5	0
26	No Patent, No Generic. , 2023, , 106-143.		0
28	Simipolitics. , 2023, , 71-105.		0
29	Supergeneric vs. Mere Commodity. , 2023, , 178-196.		0
30	RX for MX. , 2023, , 1-27.		0
31	Access, Excess. , 2023, , 144-177.		0
32	Same and Not the Same. , 2023, , 29-70.		0